Sodium Hyaluronate

精彩内容 米内网数据显示，2025年Q1重点省份实体药店药品（中+化+生）的销售规模下跌了5%左右，是近三年首跌，159个药品销售额超过1亿元。中成药市场大跌超过15%，阿胶以12亿元稳坐销冠，新一代“流感神药”飙涨1632%，翰森制药、东阿阿胶、康恩贝、云南白药、奇正集团、远大健康的独家产品均有双位数增长。 图1：重点省份实体药店药品（中+化+生）的销售情况（单位：亿元） 在重点省份实体药店，药品（中+化+生）的销售规模在2023-2024年保持稳定增长，2024年升至3372亿元，2025年Q1迎来近三年首跌，降幅在5%左右。 从药品类型来看，中成药2022-2024年占比均达到四成以上，销售额从2023年起开始有下滑态势，2023-2024年分别下跌了0.73%、3.23%，2025年Q1暴跌超过15%、占比也跌至了39%。西药（化+生）2022-2024年占比均达到五成以上，销售额则一路稳步增长，2023-2024年分别增长了6.48%、3.96%，2025年Q1也有3%以上的增长，同时占比升上61%。中成药市场“压力山大”，而西药市场则持续爆发活力。 54个中成药大卖！12亿产品稳坐销冠，康恩贝、奇正独家产品涨势喜人 2025年Q1重点省份实体药店有54个中成药（按产品名统计）销售额超过1亿元，其中独家产品占了29个。 表1：2025年Q1重点省份实体药店销售额过亿的中成药 在重点省份实体药店中成药市场，阿胶在2022-2025年Q1一直稳坐TOP1产品宝座，2024年及2025年Q1销售额接连下滑，但也是2025年Q1唯一一个销售额超过10亿元的产品，东阿阿胶、山东福牌阿胶、山东宏济堂制药集团是该产品TOP3企业。 非独家中成药中有9个产品2025年Q1销售额有正增长，包括了健胃消食片（+1.73%）、藿香正气口服液（+4.19%）、抗病毒口服液（+6.78%）、复方感冒灵颗粒（+7.20%）、六味地黄丸(浓缩丸)（+21.06%）、黄芪精（+15.03%）、六味地黄丸（+11.99%）、气血康口服液（+15.27%）、参苓健脾胃颗粒（+11.76%）。 图2：六味地黄丸(浓缩丸)的销售情况（单位：万元） 六味地黄丸(浓缩丸)是壮腰健肾药，目前已有超过60家药企获得生产批文，竞争激烈。该产品2022-2024年均在7亿元区间稳步上涨，2025年Q1大涨超过21.06%，是过亿非独家中成药中涨幅最大的产品，太极集团重庆中药二厂（+106.71%）、九芝堂、北京同仁堂科技制药（+12.02%）是该产品TOP3企业。 京都念慈菴蜜炼川贝枇杷膏以4亿元销售额成为2025年Q1最畅销的独家中成药，29个独家中成药中仅7个2025年Q1有正增长，危机不容忽视，包括了东阿阿胶的复方阿胶浆（+11.13%）、康恩贝的肠炎宁片（+20.72%）、浙江天皇药业的铁皮枫斗颗粒（+1.19%）、云南白药的云南白药气雾剂（+10.38%）和云南白药膏（+8.48%）、奇正集团的消痛贴膏（+10.32%）、德国礼达的迈之灵片（+12.39%）。 图3：康恩贝的肠炎宁片销售情况（单位：万元） 康恩贝的独家产品肠炎宁片是肠道用药，2023年在重点省份实体药店销售额超过16.8亿元，2024年虽有降幅但依然保持在12亿元以上，2025年Q1恢复正增长，涨幅超过20%，全年或将重拾2023年的辉煌。 图4：东阿阿胶的复方阿胶浆销售情况（单位：万元） 东阿阿胶的复方阿胶浆是补血用药，近几年在重点省份实体药店的销售额一直稳定增长，2024年涨至14亿元以上，2025年Q1大涨11.13%，全年有望再创新高。 105个西药火了！新一代“流感神药”大涨1632%，翰森、远大独家产品突围 2025年Q1重点省份实体药店有105个西药（化+生）销售额超过1亿元，其中独家产品占了19个。 枸橼酸西地那非片在2023年成为了西药市场TOP1产品，2024年销售额涨至接近38亿元，2025年Q1以9.4亿元继续蝉联销冠，晖致、白云山制药总厂、齐鲁制药（+30.07%）是该产品TOP3企业。 表2：2025年Q1重点省份实体药店销售额过亿且正增长的西药 整体来看，有54个西药2025年Q1销售额超过1亿元且正增长，非独家产品占了44个，新一代“流感神药”玛巴洛沙韦片大涨1632.22%，老牌“流感神药”磷酸奥司他韦胶囊也有139.66%的增长，注射用胸腺法新的增长率也达到了133.1%。 图5：两款“流感神药”的销售情况（单位：万元） 春节是流感高发季，老牌“流感神药”磷酸奥司他韦胶囊的销售规模依然巨大，2025年Q1接近7.5亿元，罗氏（+443.33%）、宜昌东阳光长江药业（+165.75%）、中山万汉制药（+20.16%）是该产品TOP3企业。 新一代“流感神药”玛巴洛沙韦片只需单次口服，阻断流感病毒的速度要快于奥司他韦，优势明显，上市以来增长迅猛，2023-2025年Q1分别增长了1138.65%、67.78%、1632.22%，2025年Q1销售额已超过3.1亿元，目前罗氏独占市场，石药集团和天晟泰丰已拿下生产批文。 还有8个非独家西药增长率超过20%，包括了地舒单抗注射液（+85.42%）、盐酸氨基葡萄糖片（+54.53%）、玻璃酸钠滴眼液（+35.77%）、注射用重组人凝血因子Ⅷ（+35.40%）、盐酸多柔比星脂质体注射液（+31.23%）、蒙脱石散（+29.80%）、糠酸莫米松凝胶（+28.27%）、乙磺酸尼达尼布软胶囊（+25.98%）。 默沙东的帕博利珠单抗注射液以4.5亿元销售额成为2025年Q1最畅销的独家西药，10个独家西药2025年Q1有正增长，其中国产独家（不含原研地产化）有翰森制药的甲磺酸阿美替尼片（+24.54%）和甲磺酸氟马替尼片（+15.93%）、艾力斯的甲磺酸伏美替尼片（+11.06%）、百济神州的泽布替尼胶囊（+30.50%）、远大健康的双歧杆菌四联活菌片（+43.97%）。 图6：翰森制药两款独家西药的销售情况（单位：万元） 翰森制药的甲磺酸阿美替尼片（2020年获批）和甲磺酸氟马替尼片（2019年获批）均为抗肿瘤国产1类新药。甲磺酸阿美替尼片2023-2024年分别增长了40.66%、62.01%，2024年销售额达到了15.7亿元，2025年Q1再有24.54%的增长；甲磺酸氟马替尼片2023-2024年分别增长了42.79%、28.78%，2024年销售额达到了4.9亿元，2025年Q1再有15.93%的增长。 图7：远大健康的双歧杆菌四联活菌片销售情况（单位：万元） 远大健康的双歧杆菌四联活菌片是止泻药及肠道抗炎/抗感染药，近几年在重点省份实体药店的销售额一直稳定增长，2023-2024年均达到了5.2亿元以上，2025年Q1再有43.97%的涨幅，市场潜力可期。 资料来源：米内网数据库 注：米内网重点省份实体药店终端竞争格局是覆盖全国17省、4个直辖市城区与镇区所有实体药店，对全品类进行连续检测的放大版城镇实体药店数据库；上述销售额以产品在终端的平均零售价计算。欢迎指正！ 免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for purchase in Japan, effective immediately following regulatory approval, insurance coverage acceptance and appropriate use criteria issuance by Japanese academic societies. First cases commenced earlier this month following the approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for Barrigel™ rectal spacer, the first and only sculptable non-animal stabilized hyaluronic acid (NASHA) rectal spacer proven to significantly reduce radiation that reaches the rectum during prostate radiation therapy.1,5,6,7“Japan commercialization represents a key milestone in our global expansion strategy for the Barrigel™ rectal spacer,” said Liam Kelly, Chairman, President and CEO of Teleflex. “This launch supports our mission to offer the next-generation, NASHA rectal spacer that enables precise, symmetrical placement1,2,7—providing physicians with effective and proven control over the shape and placement of the implant.8 We remain committed to making Barrigel™ rectal spacer the standard of care for men undergoing prostate cancer radiation therapy.” In 2022, prostate cancer was the most common cancer among men in Japan, with 104,318 new cases—accounting for 18 percent of all cancer diagnoses nationwide.9 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease.5 A U.S. clinical study found that 98 percent of men who were treated with Barrigel™ rectal spacer met the primary endpoint of achieving at least a 25 percent reduction in radiation to the rectum.1 Patients who met the primary endpoint averaged an 85 percent reduction in rectal V54 Gy radiation to the rectum, and Barrigel™ rectal spacer is proven superior in the reduction of acute and long-term Grade 1+ GI toxicity at 3 and 6 months compared to control.1,6Yoshiko Inoue, Teleflex Managing Director, Japan, said with the launch of Barrigel™ rectal spacer in Japan, more men will have access to a solution that helps minimize the rectal side effects of prostate cancer radiation therapy.1 “We’re proud to support this important advancement and remain committed to educating healthcare professionals on the value of rectal spacing and its adoption throughout Japan,” she said. Beginning in late May, training took place in Chiba, Japan under the direction of Dr. Jun Itami, who is among the top radiation oncologists in the country. “Barrigel™ rectal spacer is unique in that it does not impose time constraints during injection and offers excellent visibility under ultrasound1-4. This allows physicians to monitor the injection in real time and place the required amount precisely1,7 where needed for each individual patient,” said Dr. Itami. “As a result, a reliable distance between the prostate and rectum can be maintained, enabling safer and more robust radiation therapy planning, representing a new standard in rectal protection during radiation therapy1.” About Barrigel™ Rectal SpacerBarrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.1 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).5 Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.2,10 Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy1 and is cleared for rectal spacing in the United States, Australia, Europe and Japan.11 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease.5 For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters. Barrigel™ Rectal Spacer Important Safety InformationBarrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, it is the intent of Barrigel™ rectal spacer to reduce the radiation dose delivered to the anterior rectum. Barrigel™ rectal spacer is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time.Barrigel™ rectal spacer should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area.As with any medical treatment, there are some risks involved with the use of Barrigel™ rectal spacer. Potential complications associated with the use of Barrigel™ rectal spacer include, but are not limited to: pain associated with Barrigel™ rectal spacer injection; needle penetration of the bladder, prostate, rectal wall, rectum, or urethra; injection of Barrigel™ rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. More information on indications, contraindications, warnings and instructions for use can be found in the Instructions For Use at www.barrigel.com. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are the property of their respective owners. © 2025 Teleflex Incorporated. All rights reserved. *Study sponsored by Palette Life Sciences, now part of Teleflex** Data from the Barrigel Pivotal Study analyzed using the same methodology as the Fischer-Valuck study***Drs Gejerman, Chao, Lederer, and Orio are paid consultants of Palette Life Sciences, now part of Teleflex. References Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023).*Svatos M, Chell E, King MT et al. Med Phys (2024).*Gejerman G, Goldstein MM, Chao M et al. Pract Radiat Oncol (2023).***Williams J, Mc Millan K, Chao M et al. J Med Imag Radiat Sci (2022).Japan Injectable Gel Instructions for Use (2025)Data on file. As of 4/01/2025.King MT, Svatos M, Orio PF III et al. Pract Radiat Oncol (2023).*Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Pract Radiat Oncol. 2017;7(3):195-202.**Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021.Data on file Teleflex. 2025 Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy Developmentinvestor.relations@teleflex.com610-948-2836 Media ContactGlenn SilverFINN Partners National Media Relations Specialistglenn.silver@finnpartners.com646-871-8485 APM1275